Elderly Bone Health — Cost, Top Hospitals & Success Rates | MyMedicPlus

Bone health in older adults is a critical dimension of healthy ageing. With advancing age, the balance between osteoblastic bone formation and osteoclastic bone resorption shifts progressively toward net bone loss — a process that accelerates dramatically in women following menopause due to oestrogen withdrawal, and occurs more gradually in men due to declining testosterone. The result is osteoporosis: reduced bone mineral density (BMD) and deterioration of bone microarchitecture that significantly increases the risk of fragility fractures — fractures occurring from low-energy trauma such as a standing-height fall or, in severe cases, from minor stresses like coughing.

Osteoporosis affects an estimated 200 million people worldwide and is a leading cause of disability, hospitalisation, and loss of independence in older adults. Hip fractures carry a one-year mortality rate of 20–30% in patients over 80, and fewer than half of hip fracture survivors regain their pre-fracture level of mobility. Vertebral fractures — the most common fragility fracture — cause chronic back pain, height loss, and kyphotic deformity, and each vertebral fracture increases the risk of subsequent vertebral fracture by five-fold.

Comprehensive bone health management involves identifying individuals at elevated fracture risk using validated tools (FRAX score, DEXA scanning), initiating appropriate pharmacological therapy, optimising calcium and vitamin D status, implementing fall prevention strategies, and encouraging weight-bearing physical activity. Treatment is guided by endocrinologists, rheumatologists, geriatricians, and primary care physicians, and is highly effective at reducing fracture risk by 40–70% when adherence is maintained.

The primary condition addressed by elderly bone health programmes is osteoporosis, defined by the World Health Organization as a bone mineral density T-score of -2.5 or below at the lumbar spine or femoral neck on DEXA scan. Osteopenia (T-score -1.0 to -2.5) represents reduced bone density short of the osteoporosis threshold and warrants monitoring and lifestyle intervention, with pharmacotherapy initiated when FRAX-calculated 10-year fracture probability exceeds country-specific intervention thresholds. Secondary osteoporosis — bone loss caused by corticosteroid therapy, vitamin D deficiency, malabsorption syndromes, hyperparathyroidism, thyroid disorders, or malignancy — requires treatment of the underlying cause alongside anti-osteoporotic therapy.

Other conditions managed within elderly bone health include Paget's disease of bone (characterised by disordered bone remodelling causing pain, deformity, and elevated alkaline phosphatase), osteogenesis imperfecta in adults, and the metabolic bone consequences of cancer treatment — including aromatase inhibitor-induced bone loss in breast cancer survivors and androgen deprivation therapy-induced bone loss in prostate cancer patients. Fall prevention programmes — an integral component of bone health services — also address impaired balance, muscle weakness (sarcopenia), polypharmacy, and environmental hazards that collectively determine fracture risk.

Any adult over 50 with risk factors for osteoporosis should be assessed for bone health. High-risk groups warranting DEXA scanning include: postmenopausal women, particularly those with early menopause (before 45 years); men over 70; individuals with prior fragility fractures; long-term corticosteroid users (prednisolone 5 mg/day for 3 or more months); patients with secondary osteoporosis risk factors; and those with a strong family history of hip fracture. The FRAX tool (developed by the University of Sheffield) provides a 10-year probability of major osteoporotic fracture and hip fracture using clinical risk factors alone or combined with BMD, and is the standard instrument for guiding treatment decisions internationally.

Pharmacological treatment is generally initiated when FRAX probability exceeds country-specific thresholds (for example, 10-year major fracture probability above 10–20% depending on national guidelines) or when T-score is below -2.5, or when a fragility fracture has already occurred. Contraindications to specific therapies must be assessed individually: bisphosphonates are contraindicated in severe renal impairment (eGFR below 30 mL/min); denosumab requires monitoring for hypocalcaemia; teriparatide and abaloparatide are avoided in patients with prior radiation to the skeleton or elevated bone turnover from other causes.

Treatment of osteoporosis in older adults encompasses pharmacological, nutritional, and non-pharmacological strategies. Bisphosphonates — including alendronate (70 mg weekly oral), risedronate (35 mg weekly oral), and zoledronic acid (5 mg annual intravenous infusion) — remain the first-line pharmacological agents. They inhibit osteoclast-mediated bone resorption and reduce vertebral fracture risk by 40–70% and hip fracture risk by 25–40% in RCT evidence. Annual intravenous zoledronate is particularly useful for patients with gastrointestinal intolerance or poor adherence to oral medications. After 3–5 years of bisphosphonate therapy, reassessment is performed, and a drug holiday may be considered in low-risk patients.

Denosumab (60 mg subcutaneous injection every 6 months) is a RANK-L inhibitor increasingly used as an alternative or in patients with renal impairment. Anabolic therapies — teriparatide (PTH 1-34, 20 mcg daily subcutaneous for up to 24 months) and romosozumab (210 mg monthly subcutaneous for 12 months) — stimulate bone formation and are reserved for severe osteoporosis or patients who fracture on antiresorptive therapy. All patients should receive adequate calcium (1000–1200 mg/day from dietary and supplemental sources combined) and vitamin D (800–1000 IU/day). Weight-bearing exercise including walking, resistance training, and balance work reduces fall risk and helps maintain bone density. Shared decision-making between the patient and specialist ensures the chosen modality aligns with individual anatomy, comorbidities, risk tolerance, and personal goals. A formal consultation with a board-certified specialist, review of pre-treatment imaging or investigation results, and multidisciplinary team input for complex cases are standard practice before finalising the treatment plan.

The evidence base for osteoporosis pharmacotherapy is among the strongest in preventive medicine. Vertebral fracture risk reduction with bisphosphonates is 40–70% compared to placebo across large RCTs including the FIT, VERT, and HORIZON trials. Hip fracture risk reduction is approximately 25–40%. With denosumab (FREEDOM trial), vertebral fracture risk is reduced by 68% and hip fracture risk by 40% over 36 months. For every 1,000 patients treated with bisphosphonates for 3 years, approximately 30–50 fractures are prevented, translating to preserved independence, reduced hospitalisation, and substantially lower mortality.

Non-pharmacological interventions add meaningful benefit. Supervised exercise programmes combining balance training and resistance exercise reduce fall rates by 20–30% in community-dwelling older adults (Cochrane review evidence). Hip protectors, when worn consistently, reduce hip fracture rates by up to 60% in nursing home residents at high fall risk. Calcium and vitamin D supplementation reduces fracture risk by 10–15% in deficient populations. Fracture Liaison Service (FLS) programmes — which systematically identify and treat all patients presenting with fragility fractures — have been shown to reduce re-fracture rates by 40–60% in health system studies, representing one of the most cost-effective interventions in orthogeriatric medicine.

Pharmacological treatments for osteoporosis carry well-characterised adverse effects. Oral bisphosphonates can cause oesophageal irritation and oesophagitis — prevented by taking the medication with a full glass of water and remaining upright for 30–60 minutes. Intravenous bisphosphonates (particularly zoledronate) commonly cause an acute-phase reaction (flu-like symptoms) in the first 24–48 hours after the initial infusion, self-resolving within 72 hours and manageable with paracetamol. Jaw osteonecrosis (ONJ) — an uncommon but serious complication — affects approximately 1 in 10,000–100,000 patients on low-dose antiresorptive therapy for osteoporosis; dental review before initiating treatment is recommended.

Atypical femoral fractures — stress fractures of the subtrochanteric or diaphyseal femur — occur in a small subset of patients on long-term bisphosphonate therapy (estimated 3–50 per 100,000 person-years), predominantly after more than 5 years of use, which is why reassessment and potential drug holiday after 5 years is recommended in lower-risk patients. Denosumab carries risk of hypocalcaemia particularly in vitamin D-deficient patients, and discontinuation without transitioning to an alternative antiresorptive leads to rapid rebound bone loss and increased fracture risk — a critical clinical safety point. Teriparatide commonly causes nausea and dizziness and is contraindicated in patients with prior radiation therapy to the skeleton.

Bone health management in older adults requires structured long-term follow-up. DEXA scanning is repeated at 1–2 years after initiating treatment to assess BMD response, and at 3–5-year intervals during ongoing therapy. Biochemical markers of bone turnover (serum CTX for resorption; P1NP for formation) can be measured at 3–6 months to confirm treatment response and adherence, providing earlier feedback than DEXA. Serum 25-OH vitamin D, calcium, and renal function are monitored annually. Adherence to bisphosphonate therapy is poor in real-world practice — fewer than 50% of patients continue therapy at one year — and regular reinforcement of adherence importance significantly improves outcomes.

Fall prevention must be a standing component of elderly bone health care. Physiotherapy assessment for balance and muscle strength, medication review (deprescribing sedatives, benzodiazepines, and antihypertensives causing orthostatic hypotension), visual acuity assessment, and home hazard evaluation address modifiable fall risk factors. Fracture Liaison Services should be available to all patients presenting with their first osteoporotic fracture to prevent the 'second fracture' — the clinical imperative in orthogeriatric medicine. Annual monitoring of adherence, fracture events, pain, and functional status guides ongoing treatment decisions.

The cost of osteoporosis management includes DEXA scanning, laboratory tests, pharmacotherapy, physiotherapy, and specialist consultations. In the UK, DEXA scanning and bisphosphonate prescribing are routinely available through the NHS. In the US, DEXA scanning costs USD 100–250 out of pocket; it is covered by Medicare for women over 65 and at-risk individuals. Generic oral alendronate costs under USD 10 per month in the US, while intravenous zoledronate costs USD 400–1,000 per infusion before insurance. Denosumab costs approximately USD 1,800–2,400 per year in the US, though biosimilars are increasingly available.

For patients seeking specialist bone health evaluation abroad, India and Thailand offer comprehensive assessments at substantially lower cost. A full bone health assessment in India — including DEXA scan, FRAX calculation, comprehensive biochemical workup, and specialist consultation — typically costs USD 150–400. Annual zoledronate infusion with consultation costs USD 80–150 in India versus USD 400–1,200 in the US. Generic oral bisphosphonates are available internationally for under USD 5 per month. These cost differences make India, Thailand, and Turkey attractive destinations for retired expatriates and patients from countries with limited public healthcare access to specialist bone health services.

For patients who cannot tolerate first-line pharmacological treatments, several alternatives exist. Hormone replacement therapy (HRT) effectively preserves bone density and reduces fracture risk in postmenopausal women and may be considered in women under 60 with menopausal symptoms where cardiovascular and breast cancer risks are lower. Selective oestrogen receptor modulators (SERMs) — particularly raloxifene (60 mg daily) — preserve bone density and reduce vertebral fracture risk without stimulating breast or uterine tissue, though they increase deep vein thrombosis risk and do not reduce hip fracture risk. Calcitonin (nasal spray) has weak antiresorptive activity and limited fracture reduction evidence, and is rarely used as primary therapy today.

For patients with high fall risk in whom fracture prevention through bone density improvement alone is insufficient, comprehensive geriatric assessment, exercise programmes (particularly Tai Chi and resistance training), hip protectors, and environmental modification remain essential complements to any pharmacological strategy. Dietary calcium optimisation (dairy, fortified foods, leafy vegetables), sunlight exposure for vitamin D synthesis, and avoidance of smoking and excessive alcohol are low-cost, evidence-based interventions accessible to all patients regardless of resource setting.